ClinicalTrials.gg
Not yet recruitingNCT07877194SMT112-216Updated Oct 16, 2026

A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer

A Phase 2 interventional study of Ivonescimab (dose level 1) combined with Cadonilimab and Ivonescimab (dose level 2) combined with Cadonilimab in Renal Cell Carcinoma, Clear Cell, sponsored by Summit Therapeutics. Not yet recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Summit Therapeutics · Phase 2, Interventional, and Treatment

Updated Oct 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,142 studies in Carcinoma, Renal Cell with a site in United States — 156 open to participants now, 280 under way, 26 of them phase 3. Carcinoma, Renal Cell · United States.

Planned enrollment
263rd of 1,008
100 · median 40
Started
2026
with 42 others
Phase 2
382 of 1,142
45 open now
Primary completion
2029-04
later than 233 of 278 live
Registered
1,139th of 1,142
by date

Among the 1,142 studies in Carcinoma, Renal Cell with a site in United States, this one is the 263rd largest by planned enrollment of the 1,008 interventional ones that give a count, is one of 43 that started in 2026, is one of 382 in phase 2, reaches primary completion later than 233 of the 278 other live ones, and was the 1,139th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

156 of the 1,142 studies in Carcinoma, Renal Cell with a site in United States are open now. Recruiting first, the newest first:

151 more — sign in →

All 156 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,142 studies in Carcinoma, Renal Cell with a site in United States, or all of them as a file.
02

Study summary

This study aims to evaluate the safety and efficacy of Ivonescimab alone or in combination with Cadonilimab or Ipilimumab in the treatment of advanced clear cell renal cell carcinoma (ccRCC).

Read the detailed description

This is a multiregional, randomized, open-label Phase II clinical study to evaluate the safety and efficacy of Ivonescimab alone or in combination with Cadonilimab or Ipilimumab in the treatment of advanced clear cell renal cell carcinoma (ccRCC). Approximately 100 participants will be randomized across five treatment arms: ivonescimab in combination with cadonilimab, ivonescimab in combination with ipilimumab, ivonescimab monotherapy, or nivolumab in combination with ipilimumab.

03

Conditions studied

  • Renal Cell Carcinoma, Clear Cell

Keywords

  • Ivonescimab
  • ccRCC
  • Advanced Renal Cell Carcinoma
  • Clear Cell Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand and voluntarily sign a written form, which must be signed prior to the performance of the designated study procedures required by the study.
  2. Age ≥ 18 years both male and female.
  3. Performance Status Score (KPS) ≥ 70%.
  4. Expected survival ≥ 6 months.
  5. According to v1.1, there is at least one that is suitable for repeated and accurate measurements.
  6. Histologically or cytologically, confirmed renal cancer with a clear cell carcinoma component (ccRCC).
  7. Locally advanced or RCC not amenable to curative surgery or radiotherapy.
  8. Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  1. Locally advanced disease that is resectable or suitable for local therapy with curative intent.
  2. or cytologically confirmed renal non-clear cell carcinoma (nccRCC).
  3. Presence of active central nervous system (CNS) .
  4. Previous anti-tumor therapy toxicity has not been resolved.
  5. Have other within 5 years prior to enrollment.
  6. Known presence of active pulmonary tuberculosis and active syphilis infection.
  7. Other reasons for ineligibility as evaluated by investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Ivo 1 + Cado

    Ivonescimab (dose level 1) + Cadonilimab

    Drug: Ivonescimab (dose level 1) combined with Cadonilimab

  • Experimental
    Ivo 2 + Cado

    Ivonescimab (dose level 2) + Cadonilimab

    Drug: Ivonescimab (dose level 2) combined with Cadonilimab

  • Experimental
    Ivo + Ipi

    Ivonescimab + Ipilimumab

    Drug: Ivonescimab combined with Ipilimumab

  • Experimental
    Ivo

    Ivonescimab

    Drug: Ivonescimab

  • Active comparator
    Nivo + Ipi

    Nivolumab + Ipilimumab

    Drug: Nivolumab combined with Ipilimumab

Interventions

  • DrugIvonescimab (dose level 1) combined with Cadonilimab

    Drug pages: Ivonescimab · Cadonilimab

    Subjects will receive Ivonescimab (dose level 1) combined with Cadonilimab via intravenous infusion (IV) up to 2 years.

  • DrugIvonescimab (dose level 2) combined with Cadonilimab

    Drug pages: Ivonescimab · Cadonilimab

    Ivonescimab (dose level 2) combined with Cadonilimab via intravenous infusion (IV) up to 2 years.

  • DrugIvonescimab combined with Ipilimumab

    Drug pages: Ivonescimab · Ipilimumab

    Ivonescimab combined with Ipilimumab via intravenous infusion (IV) up to 4 cycles. Afterward, Ivonescimab for maintenance treatment up to 2 years total.

  • Ivonescimab monotherapy via intravenous infusion (IV) up to 2 years.

  • DrugNivolumab combined with Ipilimumab

    Drug pages: Nivolumab · Ipilimumab

    Nivolumab combined with Ipilimumab via intravenous infusion (IV) up to 4 cycles. Afterward, Nivolumab will be used for maintenance treatment up to 2 years total.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR per RECIST v1.1 by investigator

    Time frame: From randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years.

  2. Adverse Events (AEs)

    Adverse events (AEs) as characterized by type, incidence, severity, seriousness, and relationship to study treatment

    Time frame: At the time of initiation of the first dose through 90 days after the last dose of study treatment.

Secondary outcomes

  1. Disease Control Rate (DCR)

    DCR assessed by investigator according to RECIST v1.1.

    Time frame: From randomization to first occurrence of disease progression, death or study completion, whichever came first, assessed up to 3 years.

  2. Duration of Response (DoR)

    Duration of response (DoR) assessed by investigator according to RECIST v1.1.

    Time frame: From time of first recorded response randomization to progressive disease, or death or study completion, whichever came first, assessed up to 3 years.

  3. Progression Free Survival (PFS)

    Progression Free Survival (PFS) is defined as the time from randomization to the first documented disease progression (per RECIST v1.1) assessed by investigator or death due to any cause, whichever occurs first.

    Time frame: From randomization to progressive disease or death, whichever came first, assessed up to 3 years.

  4. Overall Survival (OS)

    Overall Survival (OS) is defined as the time from randomization to death due to any cause.

    Time frame: From randomization to death, assessed up to 4 years.

  5. Pharmacokinetics (PK)

    Serum drug concentration at different time points after administration

    Time frame: From first dose of study drug until end of treatment, assessed up to 3 years.

  6. Anti-Drug Antibodies (ADA)

    Number of subjects with detectable anti-drug antibodies (ADA).

    Time frame: From time of initiation of first dose to 30 days after end of treatment.

07

Study locations

2 sites
  • Clinical Study Site
    Los Angeles, California 90067, United States
  • Clinical Study Site
    Beijing, Beijing Municipality, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Apr 2029, 29 months later.

Of 47 industry-sponsored phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 52. This study's planned 29 months is below that.

Counting every sponsor, half of 230 studies reached it within 58 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 16, 2026
StartEst.
Oct 19, 2026
Primary completionEst.
Apr 12, 2029
CompletionEst.
Dec 12, 2029
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07877194
Lead sponsor
Summit Therapeutics
Responsible party
Sponsor
First posted
Oct 16, 2026
Start date
Oct 19, 2026 (estimated)
Primary completion
Apr 12, 2029 (estimated)
Completion
Dec 12, 2029 (estimated)
Last update
Oct 16, 2026

Study contacts

Summit Clinical Trial Information
Contact
medicalinformation@smmttx.com
1-833-256-0522

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ivonescimab · Cadonilimab · Ipilimumab

Start the discussion